Published in Ann Neurol on February 01, 2005
Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol (2005) 2.77
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology (2008) 3.64
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.04
Inflammation, the complement system and the diseases of aging. Neurobiol Aging (2005) 1.70
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain (2003) 1.70
Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis (2010) 1.68
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
PrP conformational transitions alter species preference of a PrP-specific antibody. J Biol Chem (2010) 1.62
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry (2010) 1.57
Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol (2008) 1.56
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology (2013) 1.50
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol (2006) 1.46
Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry (2010) 1.45
Clustering of Parkinson disease: shared cause or coincidence? Arch Neurol (2004) 1.42
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.41
Severe vascular disturbance in a case of familial brain calcinosis. Acta Neuropathol (2005) 1.38
Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol (2007) 1.38
Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res (2002) 1.36
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology (2004) 1.29
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. Mov Disord (2003) 1.28
Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia (2007) 1.26
The placebo effect in Parkinson's disease. Trends Neurosci (2002) 1.24
Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis (2008) 1.24
Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging (2006) 1.24
Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem (2011) 1.22
Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res (2002) 1.21
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain (2011) 1.20
Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem (2010) 1.20
Astrocytes are GABAergic cells that modulate microglial activity. Glia (2011) 1.19
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol (2011) 1.19
Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J (2010) 1.18
Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation (2008) 1.18
The placebo effect in neurological disorders. Lancet Neurol (2002) 1.18
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol (2004) 1.18
Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J (2006) 1.17
Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging (2009) 1.14
Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol (2007) 1.11
Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol (2003) 1.10
Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol (2008) 1.10
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol (2006) 1.09
Functional imaging in Parkinson disease. Neurology (2008) 1.08
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord (2004) 1.06
Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry (2004) 1.06
Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging (2002) 1.06
Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs (2005) 1.05
Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord (2006) 1.03
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging (2008) 1.03
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (2003) 1.02
Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord (2013) 1.02
Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta (2009) 1.01
Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res (2005) 1.01
Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem (2004) 1.00
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord (2008) 1.00
Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia (2010) 0.99
Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol (2004) 0.98
Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med (2004) 0.98
Mechanisms of GABA release from human astrocytes. Glia (2011) 0.96
Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia (2003) 0.96
The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof (2002) 0.94
Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord (2008) 0.94
Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging (2008) 0.93
Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol (2007) 0.93
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain (2004) 0.92
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging (2011) 0.92
Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol (2008) 0.91
Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res (2004) 0.90
Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacol Ther (2013) 0.89
The effects of exercise on cognition in Parkinson's disease: a systematic review. Transl Neurodegener (2014) 0.89
Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One (2012) 0.88
The biochemical bases of the placebo effect. Sci Eng Ethics (2004) 0.88
TDP-43 pathology in familial British dementia. Acta Neuropathol (2009) 0.88
Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Cent Nerv Syst Agents Med Chem (2009) 0.88
Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. Neurobiol Aging (2012) 0.88
The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs (2007) 0.87
Block of purinergic P2X7R inhibits tumor growth in a C6 glioma brain tumor animal model. J Neuropathol Exp Neurol (2011) 0.86
Interleukin 1alpha and interleukin 6 protect human neuronal SH-SY5Y cells from oxidative damage. Neurosci Lett (2004) 0.86
Aurin tricarboxylic acid self-protects by inhibiting aberrant complement activation at the C3 convertase and C9 binding stages. Neurobiol Aging (2012) 0.86
Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol (2007) 0.86
Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis. Exp Neurol (2002) 0.85
Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP. J Leukoc Biol (2003) 0.85
Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse (2009) 0.85
The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS One (2013) 0.85
Comparison of Vascular Perturbations in an Aβ-Injected Animal Model and in AD Brain. Int J Alzheimers Dis (2011) 0.85
Differential expression of interferon-gamma receptor on human glial cells in vivo and in vitro. J Neuroimmunol (2010) 0.84
Optineurin in Huntington's disease intranuclear inclusions. Neurosci Lett (2011) 0.84
Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Prog Brain Res (2010) 0.84
Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Exp Neurol (2009) 0.84